



Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application No. 09/944,326
 Applicant: Gleave et al
 Filing Date: August 10, 2001
 Title: TRPM-2 Antisense Therapy
 Attorney Docket No.: UBC.P-020-2

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS

	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
KAL	Butyan et al., "Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death" <i>Molecular and Cellular Biology</i> Aug. 1989, Vol. 9, No. 8, pp. 3473-3481
KAL	Millar et al., "Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous epithelium: fact or artefact?" <i>International Journal of Andrology</i> , 17:149-160 1994
KAL	Darby et al., "Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity" <i>Exp Nephrol</i> 1995; 3:234-239
KAL	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays" <i>Nature Biotechnology</i> Volume 15, June 1997, pp. 537-541
KAL	Sensibar et al., "Prevention of Cell Death Induced by Tumor Necrosis Factor alpha in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin)," <i>Cancer Research</i> . June 1, 1995, Vol. 55, pp. 2431-2437
KAL	Miyake et al., "Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer", <i>Cancer Research</i> 60, January 1, 2000, pp. 170-176
KAL	Yang et al., "Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death", <i>Proc. Nat'l. Acad. Sci. USA</i> , Vol. 97, Issue 11, pp 5907-5912, May 23, 2000
KAL	Benner, et al., "Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies", <i>Journal of Pharmacological and Toxicological Method</i> , 37:229-235 (1997)



Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application No. 09/913,325
Applicant: Gleave et al
Filing Date: August 10, 2001
Title: TRPM-2 Antisense Therapy
Attorney Docket No.: UBC.P-020

Page 2 of 2

KAL	Kadomatsu, et al, "Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle", <i>Cancer Res</i> April 1, 1993, 53(7):1480-1483
KPL	Kyprianou, et al., "bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells.", <i>Int J Cancer</i> . Jan. 27, 1997, 70(3):341-348
KAL	Wright, et al., "A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.", <i>Exp Cell Res</i> , Jan. 10, 1996, 222(1):54-60
TPN	Bruchovsky, et al., "Control of tumor progression by maintenance of apoptosis.", <i>Prostate Suppl.</i> , 1996, 6:13-21

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Karen Alfaourine
Examiner Signature

11-17-03
Date Considered